Glecaprevir/pibrentasvir
Combination drug / From Wikipedia, the free encyclopedia
Dear Wikiwand AI, let's keep it short by simply answering these key questions:
Can you list the top facts and stats about Glecaprevir/pibrentasvir?
Summarize this article for a 10 year old
Glecaprevir/pibrentasvir (G/P), sold under the brand names Mavyret and Maviret, is a fixed-dose combination medication used to treat hepatitis C.[4][5] It contains glecaprevir and pibrentasvir.[5][6] It works against all six types of hepatitis C.[4] At twelve weeks following treatment between 81% and 100% of people have no evidence of hepatitis C.[7] It is taken once a day by mouth with food.[4][5]
Combination of | |
---|---|
Glecaprevir | NS3/NS4A inhibitor |
Pibrentasvir | NS5A inhibitor |
Clinical data | |
Trade names | Mavyret, Maviret, others |
AHFS/Drugs.com | Monograph |
MedlinePlus | a617039 |
License data | |
Pregnancy category |
|
Routes of administration | By mouth |
ATC code | |
Legal status | |
Legal status | |
Identifiers | |
KEGG |
The most common side effects are headache, diarrhea, and tiredness.[7][8] In those with a history of hepatitis B, reactivation may occur.[8] It is not recommended in people with moderate to severe liver disease.[7] Glecaprevir works by blocking the protein NS3/4A protease, while pibrentasvir works by blocking NS5A.[4]
The combination was approved for medical use in the United States and Europe in 2017.[6][4] It is on the World Health Organization's List of Essential Medicines.[9]